<DOC>
	<DOCNO>NCT02167958</DOCNO>
	<brief_summary>The purpose study determine whether stem cell collect donor 's blood stream safe effective use bone marrow collect donor 's pelvic bone .</brief_summary>
	<brief_title>Nonmyeloablative Hematopoietic Cell Transplantation ( HCT ) Patients With Hematologic Malignancies Using Related , HLA-Haploidentical Donors : A Pilot Trial Peripheral Blood Stem Cells ( PBSC ) Donor Source</brief_title>
	<detailed_description>This pilot study assess safety potential efficacy haploidentical peripheral blood stem cell transplantation use nonmyeloablative preparative regimen post-transplant cyclophosphamide . The overall objective study collect efficacy safety data provide basis decide whether large study clinical efficacy warrant setting .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Subject 1 . Age &lt; 70 . 2 . Molecular base HLA type perform HLAA , B , Cw , DRB1 DQB1 locus resolution adequate establish haplo identity . A minimum match 5/10 require . An unrelated donor search require patient eligible protocol clinical situation dictate urgent transplant . Clinical urgency define 68 week referral lowlikelihood find match , unrelated donor . 3 . Subjects must meet one disease classification list : Acute leukemia ( include T lymphoblastic lymphoma ) . Remission define &lt; 5 % blast morphological characteristic acute leukemia ( e.g. , Auer Rods ) bone marrow &gt; 20 % cellularity , peripheral blood count show ANC &gt; 1000/ul , include patient CRp . Acute Lymphoblastic Leukemia high risk CR1 define least one following : Adverse cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangements White blood cell count &gt; 30,000/mcL Patients 30 year age Time complete remission &gt; 4 week Presence extramedullary disease Acute Myelogeneous Leukemia high risk CR1 define least one following : Greater 1 cycle induction therapy require achieve remission Preceding myelodysplastic syndrome ( MDS ) Presence Flt3 abnormalities FAB M6 M7 leukemia Adverse cytogenetics overall survival : associated MDS Complex karyotype ( ≥ 3 abnormality ) Any follow : inv ( 3 ) ( 3 ; 3 ) , ( 6 ; 9 ) , ( 6 ; 11 ) , + 8 [ alone abnormalities except ( 8 ; 21 ) , ( 9 ; 11 ) , inv ( 16 ) ( 16 ; 16 ) ] , ( 11 ; 19 ) ( q23 ; p13.1 ) Acute Leukemias 2nd subsequent remission Biphenotypic/Undifferentiated Leukemias 1st subsequent CR . Highrisk MDS statuspost cytotoxic chemotherapy Myelofibrosis Burkitt 's lymphoma : second subsequent CR . Lymphoma . Chemotherapysensitive ( complete partial response ; see response criterion Appendix C ) large cell , Mantle Cell Hodgkin 's lymphoma fail least 1 prior regimen multiagent chemotherapy ineligible autologous transplant relapsed/progressed autologous stem cell transplant . Marginal zone Bcell lymphoma follicular lymphoma progress least two prior therapy ( exclude single agent Rituxan ) ineligible autologous transplant relapsed/progressed autologous stem cell transplant.. 4 . Patients adequate physical function measure : Cardiac : leave ventricular ejection fraction rest must ≥ 35 % . Hepatic : bilirubin ≤ 2.5 mg/dL ; ALT , AST , Alkaline Phosphatase &lt; 5 x ULN . Renal : serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 40 mL/min/1.73m2 . Pulmonary : FEV1 , FVC , DLCO ( diffusion capacity ) ≥ 40 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation &gt; 92 % room air . Performance status : Karnofsky/Lansky score ≥ 60 % . 5 . Patients receive prior allogeneic HSCT either reject graft become tolerant graft active GVHD require immunosuppressive therapy . Donor 1 . Donors must HLAhaploidentical firstdegree relatives patient . Eligible donor include biological parent , sibling , child , halfsiblings . 2 . Age ≥ 18 year 3 . Weight ≥ 40 kg Subject 1 . HLAmatched donor able donate . 2 . Pregnancy breastfeed . 3 . Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) . Donor 1 ) Positive antidonor HLA antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>